A Multi-national Comparison of Antipsychotic Drug Use in Children and Adolescents, 2005-2012

Overview

Journal Child Adolesc Psychiatry Ment Health

Publisher Biomed Central

Date 2017 Oct 20

PMID 29046716

Citations 27

Authors

Luuk J Kalverdijk

Christian J Bachmann

Lise Aagaard

Mehmet Burcu

Gerd Glaeske

Falk Hoffmann

Irene Petersen

Catharina C M Schuiling-Veninga

Linda P Wijlaars

Julie M Zito

Affiliations

Soon will be listed here.

Abstract

Over the last decades, an increase in antipsychotic (AP) prescribing and a shift from first-generation antipsychotics (FGA) to second-generation antipsychotics (SGA) among youth have been reported. However, most AP prescriptions for youth are off-label, and there are worrying long-term safety data in youth. The objective of this study was to assess multinational trends in AP use among children and adolescents. A repeated cross-sectional design was applied to cohorts from varied sources from Denmark, Germany, the Netherlands, the United Kingdom (UK) and the United States (US) for calendar years 2005/2006-2012. The annual prevalence of AP use was assessed, stratified by age group, sex and subclass (FGA/SGA). The prevalence of AP use increased from 0.78 to 1.03% in the Netherlands' data, from 0.26 to 0.48% in the Danish cohort, from 0.23 to 0.32% in the German cohort, and from 0.1 to 0.14% in the UK cohort. In the US cohort, AP use decreased from 0.94 to 0.79%. In the US cohort, nearly all ATP dispensings were for SGA, while among the European cohorts the proportion of SGA dispensings grew to nearly 75% of all AP dispensings. With the exception of the Netherlands, AP use prevalence was highest in 15-19 year-olds. So, from 2005/6 to 2012, AP use prevalence increased in all youth cohorts from European countries and decreased in the US cohort. SGA were favoured in all countries' cohorts.

Citing Articles

Incidence and trend of cardiac events among children and young adults exposed to psychopharmacological treatment (2006-2018): A nationwide register-based study.

Elmowafi H, Kindblom J, Halldner L, Gyllenberg D, Naumburg E Br J Clin Pharmacol. 2024; 91(3):817-828.

PMID: 39448545 PMC: 11862795. DOI: 10.1111/bcp.16321.

Psychotropic drug use among children and adolescents in the Nordic countries: a systematic review.

Ollerup D, Rasmussen L, Elkrog S, Stoltz-Andersen M, Stubmark H, Wesselhoeft R Eur Child Adolesc Psychiatry. 2024; 34(3):903-919.

PMID: 39115685 DOI: 10.1007/s00787-024-02545-0.

Early-life risperidone alters locomotor responses to apomorphine and quinpirole in adulthood.

Bardgett M, Griffith M, Robinson K, Stevens R, Gannon M, Knuth M Behav Brain Res. 2024; 473:115171.

PMID: 39094954 PMC: 11345744. DOI: 10.1016/j.bbr.2024.115171.

Evaluation of the Safer Use of Antipsychotics in Youth Study on Population Level Antipsychotic Initiation: An Interrupted Time Series Analysis.

West L, Mooney S, Chavez L, Beck A, Clarke G, Pabiniak C J Child Adolesc Psychopharmacol. 2024; 34(7):310-318.

PMID: 38743639 PMC: 11807901. DOI: 10.1089/cap.2024.0007.

Psychotropic Medication Prescribing for Children and Adolescents After the Onset of the COVID-19 Pandemic.

Valtuille Z, Acquaviva E, Trebossen V, Ouldali N, Bourmaud A, Sclison S JAMA Netw Open. 2024; 7(4):e247965.

PMID: 38652474 PMC: 11040414. DOI: 10.1001/jamanetworkopen.2024.7965.

References

Kalverdijk L, Tobi H, van den Berg P, Buiskool J, Wagenaar L, Minderaa R . Use of antipsychotic drugs among Dutch youths between 1997 and 2005. Psychiatr Serv. 2008; 59(5):554-60. DOI: 10.1176/ps.2008.59.5.554. View

McLeod J, Pescosolido B, Takeuchi D, White T . Public attitudes toward the use of psychiatric medications for children. J Health Soc Behav. 2004; 45(1):53-67. DOI: 10.1177/002214650404500104. View

Penfold R, Stewart C, Hunkeler E, Madden J, Cummings J, Owen-Smith A . Use of antipsychotic medications in pediatric populations: what do the data say?. Curr Psychiatry Rep. 2013; 15(12):426. PMC: 4167011. DOI: 10.1007/s11920-013-0426-8. View

Correll C . Antipsychotic use in children and adolescents: minimizing adverse effects to maximize outcomes. J Am Acad Child Adolesc Psychiatry. 2008; 47(1):9-20. DOI: 10.1097/chi.0b013e31815b5cb1. View

Glennon J, Purper-Ouakil D, Bakker M, Zuddas A, Hoekstra P, Schulze U . Paediatric European Risperidone Studies (PERS): context, rationale, objectives, strategy, and challenges. Eur Child Adolesc Psychiatry. 2013; 23(12):1149-60. PMC: 4246122. DOI: 10.1007/s00787-013-0498-3. View

Correll C, Leucht S, Kane J . Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry. 2004; 161(3):414-25. DOI: 10.1176/appi.ajp.161.3.414. View

Murphy A, Gardner D, Kisely S, Cooke C, Kutcher S, Hughes J . System struggles and substitutes: A qualitative study of general practitioner and psychiatrist experiences of prescribing antipsychotics to children and adolescents. Clin Child Psychol Psychiatry. 2015; 21(4):634-648. PMC: 5094295. DOI: 10.1177/1359104515617518. View

Correll C, Lencz T, Malhotra A . Antipsychotic drugs and obesity. Trends Mol Med. 2010; 17(2):97-107. PMC: 3053585. DOI: 10.1016/j.molmed.2010.10.010. View

Loy J, Merry S, Hetrick S, Stasiak K . Atypical antipsychotics for disruptive behaviour disorders in children and youths. Cochrane Database Syst Rev. 2012; (9):CD008559. DOI: 10.1002/14651858.CD008559.pub2. View

10.

Maguire A, Blak B, Thompson M . The importance of defining periods of complete mortality reporting for research using automated data from primary care. Pharmacoepidemiol Drug Saf. 2008; 18(1):76-83. DOI: 10.1002/pds.1688. View

11.

Correll C, Carlson H . Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. J Am Acad Child Adolesc Psychiatry. 2006; 45(7):771-91. DOI: 10.1097/01.chi.0000220851.94392.30. View

12.

Horsfall L, Walters K, Petersen I . Identifying periods of acceptable computer usage in primary care research databases. Pharmacoepidemiol Drug Saf. 2012; 22(1):64-9. DOI: 10.1002/pds.3368. View

13.

Schmid I, Burcu M, Zito J . Medicaid prior authorization policies for pediatric use of antipsychotic medications. JAMA. 2015; 313(9):966-8. DOI: 10.1001/jama.2015.0763. View

14.

Pringsheim T, Hirsch L, Gardner D, Gorman D . The pharmacological management of oppositional behaviour, conduct problems, and aggression in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, and conduct disorder: a systematic review and.... Can J Psychiatry. 2015; 60(2):52-61. PMC: 4344947. DOI: 10.1177/070674371506000203. View

15.

Correll C, Manu P, Olshanskiy V, Napolitano B, Kane J, Malhotra A . Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA. 2009; 302(16):1765-73. PMC: 3055794. DOI: 10.1001/jama.2009.1549. View

16.

de Bildt A, Mulder E, Scheers T, Minderaa R, Tobi H . Pervasive developmental disorder, behavior problems, and psychotropic drug use in children and adolescents with mental retardation. Pediatrics. 2006; 118(6):e1860-6. DOI: 10.1542/peds.2005-3101. View

17.

Blak B, Thompson M, Dattani H, Bourke A . Generalisability of The Health Improvement Network (THIN) database: demographics, chronic disease prevalence and mortality rates. Inform Prim Care. 2012; 19(4):251-5. DOI: 10.14236/jhi.v19i4.820. View

18.

Moffitt T . Adolescence-limited and life-course-persistent antisocial behavior: a developmental taxonomy. Psychol Rev. 1993; 100(4):674-701. View

19.

Zito J, Tobi H, de Jong-van den Berg L, Fegert J, Safer D, Janhsen K . Antidepressant prevalence for youths: a multi-national comparison. Pharmacoepidemiol Drug Saf. 2006; 15(11):793-8. DOI: 10.1002/pds.1254. View

20.

Patten S, Waheed W, Bresee L . A review of pharmacoepidemiologic studies of antipsychotic use in children and adolescents. Can J Psychiatry. 2012; 57(12):717-21. DOI: 10.1177/070674371205701202. View